The cost of sequencing a human genome has dropped significantly over the past years and genome editing is enabling new breakthroughs in medicine.
On the upcoming webcast, The Power of Genome Editing: What Investors Should Know, Manisha Samy, Analyst Genomic Revolution at ARK Invest, and Renato Leggi, Product Specialist for ARK Invest, will touch upon CRISPR, biotech’s breakthrough of the century, and how it will have a profound impact on the world’s most salient issues, especially as its toolbox expands.
As a way to tap into the potential growth of the genomic revolution, ETF investors may look to the ARK Genomic Revolution Multi-Sector Fund (NYSEArca: ARKG). ARKG provides “exposure to CRISPR, gene editing, therapeutics, agricultural biology and health care innovation,” according to ARK Invest.
“Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. The companies held in ARKG may develop, produce or enable,” ARK Invest added.
Specifically, ARKG covers sub-sectors like Gene Therapy (24.1%), Targeted Therapeutics (17.5%), Targeted Therapeutics (15.6%), Beyond DNA (13.9%) and Molecular Diagnostics (11.5%).